Biotechnology Acquisitions in Arizona
Showing 4 transactions.
-
- Buyer
- Ally Biotech
- Target
- Chill Pill (soft gel cap line)
- Seller
- Desert Medical Campus, Inc.
- Industry
- Biotechnology
- Location
- Arizona, United States
- Type
- Buyout
Ally Biotech, a Payson, Arizona-based cannabinoid delivery company, acquired the Chill PillTM soft gel cap brand and related assets from Desert Medical Campus, Inc. in an all-cash transaction. The purchase adds a leading THC soft gel product line (distributed in ~40 Arizona dispensaries) to Ally Biotech’s Lipofusion delivery platform and supports planned product expansion and team integration in Payson, Arizona.
-
September 28, 2021
- Buyer
- SCHOTT MINIFAB (SCHOTT)
- Target
- Applied Microarrays Inc.
- Industry
- Biotechnology
- Location
- Arizona, United States
- Type
- Buyout
SCHOTT MINIFAB, a subsidiary of SCHOTT, has agreed to acquire Applied Microarrays Inc. (AMI), a Tempe, Arizona–based developer and manufacturer of DNA and protein microarrays and biosensors. The deal expands SCHOTT's bioscience and microarray printing capabilities and increases its manufacturing footprint in the United States to better support diagnostics and point-of-care customers.
-
April 2, 2021
- Buyer
- IMV Technologies
- Target
- Genetirate
- Seller
- Genetirate, Hatch.Blue
- Industry
- Biotechnology
- Location
- Arizona, United States
- Type
- Buyout
French animal-reproduction specialist IMV Technologies has acquired Genetirate, a U.S.-based aquaculture biotechnology startup founded at the University of Arizona. The deal brings Genetirate's metabolic-rate sorting technology into IMV's portfolio to accelerate sustainable aquaculture production, particularly for salmon and trout.
-
October 22, 2019
- Buyer
- The Pritzker Organization, Pritzker Family Business Interests (advised by The Pritzker Organization)
- Target
- Systems Oncology, LLC
- Industry
- Biotechnology
- Location
- Arizona, United States
- Type
- Growth capital
Pritzker Family Business Interests, advised by The Pritzker Organization, participated in the first closing of Systems Oncology's Series B financing. The growth capital will fund discovery research and pre-clinical development of Systems Oncology's AI-driven cancer therapeutics platform, and TPO will take a board seat.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.